Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future

References

• Brown EJ, Albers MW, Shin TB et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature369, 756–758 (1994).
   PubMed Web of Science ®Google Scholar
• Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc. Natl Acad. Sci. USA91, 12574–12578 (1994).
   PubMed Web of Science ®Google Scholar
• Sabatini DM, Erdjument-Bromage H, Lui M et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell78, 35–43 (1994).
   PubMed Web of Science ®Google Scholar
• Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science253, 905–909 (1991).
   PubMed Web of Science ®Google Scholar
• Kotilingam D, Lev DC, Lazar AJF, Pollock RE. Staging soft-tissue sarcoma: evolution and change. CA Cancer J. Clin.56, 282–229 (2006).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin.57, 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Borden EC, Baker LH, Bell RS et al. Soft tissue sarcomas of adults: state of the translational science. Clin. Can. Res.9, 1941–1956 (2003).
   PubMed Web of Science ®Google Scholar
• Henley ML, Maki RG, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol.20, 2824–2831 (2002).
   PubMed Web of Science ®Google Scholar
• Bay J-O, Ray-Coquard I, Fayette J et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcoman: a retrospective analysis. Int. J. Cancer119, 706–711 (2006).
   PubMed Web of Science ®Google Scholar
• van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumors: a Phase I study. Lancet358, 1421–1423 (2001).
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomixed trial. Lancet364, 1127 (2004).
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev.18, 1926–1945 (2004).
   PubMed Web of Science ®Google Scholar
• Peterson RT, Beal PA, Comb MJ, Schreiber SL. FKBP12-rapamycin-associated protein (FRAP) autophosphorylates at serine 2481 under translationally repressive conditions. J. Biol. Chem.275, 7416–7423 (2000).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Hara K, Inoue H et al. Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro. Genes Cells5, 765–775 (2000).
   PubMed Web of Science ®Google Scholar
• Brunn GJ, Hudson CC, Sekulic A et al. Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science277, 99–101 (1997).
   PubMed Web of Science ®Google Scholar
• Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA95, 1432–1437 (1998).
   PubMed Web of Science ®Google Scholar
• Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet.37(1), 19–24 (2005).
   PubMed Web of Science ®Google Scholar
• Ali IU, Schriml LM, Dean M. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. J. Natl Cancer Inst.91, 1922–1932 (1999).
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci.28, 573–576 (2003).
   PubMed Web of Science ®Google Scholar
• Goncharova EA, Goncharova DA, Eszterhas A et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. J. Biol. Chem.277, 30958–30967 (2002).
   PubMed Web of Science ®Google Scholar
• Kwiatkowski DJ, Zhang H, Bandura JL et al. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in TSC1 null cells. Hum. Mol. Genet.11, 525–534 (2002).
   PubMed Web of Science ®Google Scholar
• Podsypanina K, Lee RT, Politis C et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in PTEN+/- mice. Proc. Natl Acad. Sci. USA98, 10320–10325 (2001).
   PubMed Web of Science ®Google Scholar
• Corradetti MN, Inoki K, Bardeesy N et al. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and the Peutz–Jeghers syndrome. Genes Dev.18, 1533–1538 (2004).
   PubMed Web of Science ®Google Scholar
• Shaw RJ, Bardeesi N, Manning BD et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell6, 91–99 (2004).
   PubMed Web of Science ®Google Scholar
• Hara K, Maruki Y, Long X et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell110, 177–189 (2002).
   PubMed Web of Science ®Google Scholar
• Kim DH, Sarbassov DD, Ali SM et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell110, 163–175 (2002).
   PubMed Web of Science ®Google Scholar
• Dutcher JP. Mammalian target of rapamycin inhibition. Clin. Cancer Res.10, 6382–6387 (2004).
   PubMed Web of Science ®Google Scholar
• Foster DA. Regulation fo mTOR by phosphatidic acid? Cancer Res.67, 1–4 (2007).
   PubMed Web of Science ®Google Scholar
• Fang Y, Vilella-Bach M, Bachmann R et al. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science294, 1942–1945 (2001).
   PubMed Web of Science ®Google Scholar
• Chen Y, Roderik V, Foster FA. Alternative phospholipase D/mTOR survival signal in human breast cancer cells. Oncogene24, 672–979 (2005).
   PubMed Web of Science ®Google Scholar
• Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat. Rev.8, 63–87 (1981).
   PubMed Web of Science ®Google Scholar
• Dilling MB, Dias P, Shapiro DN et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res.54, 903–907 (1994).
   PubMed Web of Science ®Google Scholar
• Dancey JE. Therapeutic targets: mTOR and related pathways. Cancer Biol. Ther.5(9), 1065–1073 (2006).
   PubMed Web of Science ®Google Scholar
• Decker T, Hipp S, Ringshausen I et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A and surviving. Blood101, 278–285 (2003).
   PubMed Web of Science ®Google Scholar
• Luo Y, Marx SO, Kiyokawa H et al. Rapamycin resistance tied to defective regulation of p27Kip1. Mo.l Cell Biol.16, 6744–6751 (1996).
   Web of Science ®Google Scholar
• Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. Curr. Opin. Oncol.18, 360–362 (2006).
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Baker LH, Maki RG. Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. Proc. Am. Soc. Clin. Oncol.24, A9503 (2006).
   Google Scholar
• Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol.22, 2336–2347 (2004).
   PubMed Web of Science ®Google Scholar
• Peralba JM, deGraffenried L, Friedrichs W et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res.9, 2887–2892 (2003).
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Rowinsky E, Erlichman C et al. A Phase I and pharmacological study of CCI-779, a rapamycin ester cell cycle inhibitor. Ann. Oncol.11, 133 (2000) (Abstract 606O).
   PubMedGoogle Scholar
• Hidalgo M, Rowinsky E, Erlichman C et al. Phase I and pharmacological study of CCI-779, a cell cycle inhibitor. Proceedings of the 11th NCI-EORTC-AACR Symposium on New Drugs in Cancer Therapy. Clin. Can. Res.6, A413 (2000).
   Google Scholar
• Hidalgo M, Buckner JC, Erlichman C et al. A Phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res.12(19), 5755–5763 (2006).
   PubMed Web of Science ®Google Scholar
• Chang SM, Kuhn J, Wen P et al. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest. New Drugs22, 427–435 (2004).
   PubMed Web of Science ®Google Scholar
• Okuno SH, Mahoney MR, Bailey HH et al. A multicenter Phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). Proc. Am. Soc. Clin. Oncol.24, A9504 (2006).
   Google Scholar
• O’Donnell A, Faivre S, Judson I et al. A Phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumors. Proc. Am. Soc. Clin. Oncol.22, A803 (2003).
   Google Scholar
• Tabernero J, Rojo F, Burris E et al. A Phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol.24, A3007 (2005).
   Web of Science ®Google Scholar
• Mita MM, Rowinsky EK, Mita AC et al. Phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of AP23573, an mTOR inhibitor, administered IV daily × 5 every other week in patients (pts) with refractory or advanced malignancies. Proc. Am. Soc. Clin. Oncol.23, 3076 (2004).
   Google Scholar
• Desai AA, Janisch L, Berk LR et al. A Phase I trail of a novel mTOR inhibitor AP23573 administered weekly (wkly) in patients (pts) with refaractory or advanced malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis. Proc. Am. Soc. Clin. Oncol.23, A3150 (2004).
   Google Scholar
• Chawla SP, Tolcher AW, Staddon AP et al. Updated results of a Phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. Proc. Am. Soc. Clin. Oncol.24, A9505 (2006).
   Google Scholar
• Sankhala KK, Chawla SP, Iagaru A et al. Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan. Proc. Am. Soc. Clin. Oncol.23, A9028 (2005).
   Google Scholar
• Van Oosterom AT, Dumez H, Desai J et al. Combination signal transduction inhibition: a Phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. Proc. Am. Soc. Clin. Oncol.22, A3002 (2004).
   Web of Science ®Google Scholar
• Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev.5, 671–682 (2006).
   Google Scholar
• von Mehren M. New therapeutics for soft-tissue sarcomas in adults. Oncology21(1), 123–126 (2007).
   PubMed Web of Science ®Google Scholar
• Buck E, Eyzaguirre A, Brown E et al. Rapamycin synergizes with the epidermal growth factor receptor erlotinib in non-small-cell lung, pancreatic, colon and breast tumors. Mol. Cancer Ther.5(11), 2676–2684 (2006).
   PubMed Web of Science ®Google Scholar
• Ikezoe T, Nishioka C, Tasaka T et al. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol. Cancer Ther.5(10), 2522–2530 (2006).
   PubMed Web of Science ®Google Scholar